Inogen's overall fourth-quarter 2024 results continue to gain from higher business-to-business sales.

Foot Locker's fiscal fourth-quarter results reflect lower y/y revenues. The gross margin expands 300 bps to 29.6% in the quarter.

Masimo's fourth-quarter 2024 results continue to benefit from the strength in its Healthcare and Non-healthcare businesses.

Strength in Avanos' Digestive Health segment drives its fourth-quarter 2024 performance despite global macroeconomic challenges.

Catalyst stock gains on strong fourth-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse sales.

BBWI's fourth-quarter results reflect lower y/y revenues and higher earnings. The operating margin increases 40 basis points to 24.3% in the quarter.

TFX benefits from a diversified product portfolio in the fourth quarter of 2024, with strength in the Surgical and Interventional segments.

Solventum's fourth-quarter earnings showcase strong segmental performance. However, declining margins raise concerns.

BHC's fourth-quarter adjusted earnings and revenues beat estimates driven by Xifaxan. The guidance for 2025 is positive.

Clover Health's fourth-quarter 2024 results continue to benefit from the strength of its strong member retention. Strong revenue outlook bodes well.